news analysis advocacy

Support AfricaFocus and independent bookstores!

Make non-profit your first stop for buying books.
See books recommended by AfricaFocus.


Visit the AfricaFocus
Country Pages

Burkina Faso
Cape Verde
Central Afr. Rep.
Congo (Brazzaville)
Congo (Kinshasa)
Cte d'Ivoire
Equatorial Guinea
São Tomé
Sierra Leone
South Africa
South Sudan
Western Sahara

Get AfricaFocus Bulletin by e-mail!

Format for print or mobile

Africa: End of AIDS in Sight, 1

AfricaFocus Bulletin
Jul 27, 2012 (120727)
(Reposted from sources cited below)

Editor's Note

"Even without a vaccine or a cure, it became clear this week that science has given us the tools we need to dramatically change the course of the HIV/AIDS pandemic and ultimately end AIDS. Any argument that this cannot be achieved because we do not have evidence-based tools is no longer valid. Science has given us the tools. Now they must be applied." - Anthony Fauci, at the opening of this week's International AIDS Conference

Amid the plethora of reports, commentaries, meetings, and demonstrations this week at the International AIDS Conference in Washington, the consensus was wider than ever that success against the AIDS pandemic is in sight, but only if existing knowledge is applied with sufficient resources and commitment.

Two AfricaFocus Bulletins today select among the most readable and informative reports and commentaries appearing during the week.

This AfricaFocus Bulletin, sent out by e-mail today and available on the web at, contains several other recent articles, including (1) a summary article from PlusNews on the prospects for an "and to AIDS," (2) an op-ed by Anthony Fauci on the same theme, (3) an analysis by AIDS activist Mark Harrington on the Obama administration response to the AIDS pandemic, with proposals for additional action.

Another AfricaFocus Bulletin, not sent out by e-mail but available on the web at, contains (1) a report from PlusNews focused on increases in domestic investment on AIDS in affected African countries, (2) a commentary from Doctors without Borders on the need for stepped-up commitment by donors, (3) a news release from Kaiser Family Foundation and UNAIDS on trends in donor financing, and (4) a commentary from Huffington Post on how U.S. Trade policy is undermining the prospects for affordable generic drugs for AIDS and other diseases.

For previous AfricaFocus Bulletins on health issues, and additional background links, visit

++++++++++++++++++++++end editor's note+++++++++++++++++

HIV/AIDS: "End of AIDS" in sight

July 23, 2012

This report online (including additional links):

Washington DC, 23 July 2012 (Plusnews) - There is no cure or vaccine yet, but "the end of AIDS" was the buzzword at the opening ceremony of the International AIDS conference in Washington DC on 22 July.

Wishful thinking? Not for Michel Sidibé, executive director of UNAIDS, who told over 20,000 delegates that "this time, it is different", or for Jim Yong Kim, the new President of the World Bank Group and the first to address an international AIDS conference. "We can end AIDS, we must end AIDS. The challenge we face is great, but as I look out at all of you today, I can actually see the end of AIDS," said Kim.

Sidibé's list of how to reach the end of AIDS is not new: scale up treatment-as-prevention, put 15 million on people treatment by 2015, eliminate new infections in children, and close the funding gap.

Nonetheless there is reason for optimism. For the first time there are more people on treatment than those who need it, and new infections worldwide have declined by 20 percent since 2001. In South Africa at least 300,000 people started treatment in 2011, 150,000 started in Zimbabwe, and in China the number of people on treatment doubled in one year.

Even scientists are hopeful and on 19 July released a road map ahead of the conference for research toward a cure for HIV - the first time scientists have come up with a coordinated plan to tackle the virus.

"The science has been telling us for some time now that achieving a cure for HIV infection could be a realistic possibility. The time is right to take the opportunity to try and develop an HIV cure - we might regret never having tried," said Françoise Barré-Sinoussi, the co-discoverer of HIV and Director of the Regulation of Retroviral Infections Unit at the Institut Pasteur in Paris.

However, money remains a major obstacle. The new UNAIDS report says there is still a large gap in global funding for HIV, estimated to reach $7 billion by 2015.

"From many places in the developed world I am hearing, 'We cannot afford to keep our promises; we have our own problems at home.' Financial commitment from developed countries is declining... this gap is killing people," Sidibe warned delegates.

The last International AIDS Conference was held in the US in 1990, but restrictions on the entry of people living with HIV into the country prohibited holding another conference in America until now.

President Barack Obama lifted the travel ban in 2010; the Republic of Korea announced at the conference that it had also removed its travel restrictions on HIV-positive people.


An opportunity to end the AIDS pandemic

By Anthony S. Fauci

Washington Post, July 27, 2012

I was honored to deliver the opening scientific plenary lecture Monday at the 19th International AIDS Conference in Washington. The last time the meeting took place here was 25 years ago, and the mood was entirely different. In 1987, our scientific knowledge about this exploding epidemic was in its infancy. What has since been accomplished emboldened the organizers to make this yearâTMs conference theme âTurning the Tide Togetherâ - and allowed me to speak of a possible end to the AIDS pandemic.

The medical advances discussed at this meeting result from a 30-year scientific journey characterized by incremental progress in understanding HIV and how it causes disease, the development of treatments and prevention tools, the testing of these interventions in clinical trials, and implementation of these tools in communities worldwide. What stands out in my mind from this weekâTMs presentations is that interventions previously proved to work in controlled clinical trials are now - over and over again - proving effective outside the research setting, in the real world, in poor and rich communities alike. The pieces are coming together.

More than 8 million people in low- and middle-income countries are receiving lifesaving antiretroviral drugs. These medications averted 840,000 deaths in 2011 alone, one of the most extraordinary accomplishments in public health history. Still, 9 million HIV-infected people who need therapy are not receiving it. In the United States, more than 1.1 million people are infected with HIV and 20 percent are not aware of it. This group inadvertently transmits the vast majority of the approximately 50,000 new infections that occur annually in the United States. Researchers and health departments are pursuing new approaches to test people for HIV and to provide treatment and care as well as the support that enables HIV-infected individuals to maximize benefits from medical and social services. As discussed at the conference, such efforts are underway here in Washington, in other U.S. cities with high HIV infection rates and in other countries. Lives are being saved.

Besides their lifesaving role as treatment, antiretroviral drugs can prevent HIV infection. By significantly lowering virus levels, they dramatically reduce the risk that infected people will transmit HIV to sexual partners or, in the case of pregnant women, to their infants. This concept has been proved in rigorous clinical trials, and this week we saw new data that the results may be even stronger than earlier reports. We also saw evidence of real-world public health benefits at the community, regional and national levels: As antiretroviral coverage has been scaled up, incidence of HIV infection has gone down. Treatment as prevention, if properly implemented and used along with condoms and other proven tools, will significantly slow the trajectory of the pandemic.

Another scientifically proven prevention approach is voluntary medical male circumcision, which reduces a heterosexual manâTMs risk of acquiring HIV by 50 to 60 percent, an effect that increases over time. We are seeing reductions in HIV incidence in settings in Africa where adult male circumcision is being scaled up as part of a comprehensive HIV prevention strategy.

Studies have also shown that people at high risk of HIV infection can reduce that risk by taking an antiretroviral pill daily - a method known as pre-exposure prophylaxis, or PrEP. The Food and Drug Administration recently approved a pill combining two antiretrovirals for certain high-risk groups to use as oral PrEP together with condoms and other prevention tools. Antiretrovirals for use at the genital mucosa also have shown promise as PrEP and, as discussed this week, are being tested in vaginal rings that need to be replaced just once a month. As with many treatment and prevention tools, the effectiveness of PrEP is directly related to how well people adhere to the prescribed regimen, underscoring that behavioral factors must be addressed when rolling out any intervention. Biologically based and behaviorally based interventions are both needed.

Major research challenges remain, notably in developing a vaccine and a cure for HIV. But even without a vaccine or a cure, it became clear this week that science has given us the tools we need to dramatically change the course of the HIV/AIDS pandemic and ultimately end AIDS. Any argument that this cannot be achieved because we do not have evidencebased tools is no longer valid. Science has given us the tools. Now they must be applied.

Ending the HIV pandemic is an enormous and multifaceted challenge, but we know it is possible. Yet it will not happen spontaneously. It will require a global commitment of countries, governments and communities to strengthen their health-care systems and build the capacity to provide HIV treatment and prevention. We need donors and partners to continue their investments, and we need new donor organizations and countries to step up. We must enhance what works and eliminate what does not, overcome legal and political barriers, and remove the stigma associated with HIV.

The global community has a historic opportunity based on solid scientific evidence to end the AIDS pandemic, opening the door to an AIDS-free generation.

Africa: Obama's to-Do List Towards Ending the Aids Epidemic

25 July 2012

Health-e (Cape Town)

Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS - but only if Obama sustains funding. By Mark Harrington

Mark Harrington since 2002 has been the executive director of the Treatment Action Group, which he co-founded in 1992 after four years working with the Treatment + Data Committee of ACT UP/New York. He was awarded a MacArthur Fellowship in 1997.

Four years ago, President Obama's election generated hope for new American leadership in the fight against AIDS here at home and around the world. On that day, South Africa's Treatment Action Campaign - the movement which combined massive demonstrations with sophisticated insider legal cases and science-based activism to force South Africa to create the world's largest HIV treatment program - recalledhis visit to their offices in the township of Khayelitsha, Western Cape, in August of 2006, and how it had urged him to run for president to have a chance to fulfill his commitment to addressing AIDS.

"Obama took a strong position on preventing and treating HIV/AIDS," the group recalled in 2008, "and was critical of President Mbeki and the South African government's response to the epidemic," then expressed through a deadly form of HIV denialism.

Since becoming president, Obama has continued to talk the talk, promising last December on World AIDS Day to lead the way towards an AIDS-free generation, and to increase U.S. support for global HIV treatment to cover antiretroviral therapy (ART) for six million people around the world by the end of 2013. That makes his silence this week, during the first International AIDS Conference to be held on American soil since the 1990 gathering during the George H.W. Bush administration, all the more striking.

Obama simply hasn't walked the walk when it comes to funding for AIDS. In fact, earlier this year, he proposed a shocking cut of $550 million to the President's Emergency Plan for AIDS Relief (PEPFAR), the most successful U.S.-funded global health program in history.

At first, the administration failed to provide any explanation for such drastic cuts, which could put the lives of thousands who depend on the United States to pay for treatment at risk. Later, in response to pressurefrom the Treatment Action Group and its activist colleagues, administration officials claimed that they had been so successful in reducing costs that they could reach the target of getting medicines to 6 million during 2013 even with dramatically reduced funding.

It's true that costs have gone down. Earlier this week, the Clinton Health Access Initiative released data showing that the cost of providing HIV care and treatment has dramatically fallen in the past two years due to increased use of generic medications and overall program efficiencies. The annual cost of HIV care in Ethiopia, Malawi, Rwanda, and Zambia -- including drugs, lab costs, and health worker salaries -- is now just $200, while in more developed South Africa it is $682. In her speech to the International AIDS Conference on Monday, Secretary of State Hillary Clinton indicated that these economies of scale enabled PEPFARsupported programs to enroll 600,000 people in the last six months, compared with 700,000 in the past fiscal year.

With these successes in hand, the Obama administration could easily have proposed a more rapid scale-up towards unmet HIV prevention and treatment needs, rather than slashing PEPFAR. There are plenty of global health needs to which the funds saved on "efficiencies" could have been applied - expanding TB testing in mothers and children, purchasing GeneXpert TB test kits, which can diagnose the disease and its most common drug-resistance patterns in two hours rather than the two weeks or more traditional TB culture takes - as well as expanding ART treatment slots and growing maternal and child health programs. All these would have been steps forward towards the making administration's AIDS-free generation promise a reality.

Instead, the administration decided to pocket the savings, leaving millions of people out in the cold.

Some people even wonder if the president's lack of enthusiasm for PEPFAR heralds the program's demise next year, when it is due to be reauthorized by Congress. PEPFAR was launched in 2003 by President George W. Bush and, along with the Global Fund to Fight AIDS, Tuberculosis and Malaria, has channeled $39 billion in U.S. aid towards HIV treatment and prevention efforts (as well as the fights against TB and malaria) around the world, making the United States the single largest source of dollars addressing the global HIV pandemic. Four-and-a-half million people today are receiving life-saving HIV treatment through PEPFAR in low and middle-income countries in Africa, Asia, the Caribbean, and South America.

Had Obama attended the International AIDS Conference (Secretary of State Hillary Clinton, HHS Secretary Kathleen Sebelius, PEPFAR chief Eric Goosby, and NIH AIDS supremo Anthony Fauci and other members of the administration have been speaking or attending in his stead), he would have heard deep gratitude for the U.S. role in responding to the HIV epidemic around the globe. He would have heard optimism that the world is on the cusp of being able to do something long thought unthinkable -- actually bring about an end to the AIDS pandemic.

But since he won't be there, here's a to do list the president should consider if he wants to walk the walk to truly begin to make that happen:

1. Fully fund PEPFAR and support its reauthorization in 2013. Restore the $546 million in proposed cuts to PEPFAR in fiscal year 2013, and begin planning now for the program's upcoming legislative reauthorization in 2013.

2. Restore cuts to the Centers for Disease Control and Prevention (CDC) tuberculosis program. TB is the leading cause of HIV related death worldwide, yet the last budget continues a deplorable pattern of cutting the CDC's TB control budget. As a result of the cuts, the New York City Department of Health is being forced this week to suspend an innovative pilot program to treat cases of latent TB infection with a three-month course of treatment, instead of the older standard nine-month course, which imposes much greater inconveniences on patients and health workers alike.

3. Fully support the Global Fund to Fight AIDS, Tuberculosis and Malaria, and enable it to replenish depleted funding coffers for countries trying to expand their programs for prevention, care, and treatment of the three diseases, which often spread in tandem and occur at the highest rates in the same countries.

4. Reject the congressional ban on federal funding for needle exchange. As part of last year's budget deal, Obama conceded to congressional demands that the ban on federal funding for needle exchange be reinstated. The administration did this despite knowing that needle exchange programs save lives and reduce HIV transmission -- and despite having reversed the previous ban. Last year's decision was wrong and could lead to unnecessary increases in HIV incidence among drug users and their sex partners.

5. Revise and revitalize the National HIV/AIDS Strategy (NHAS) to incorporate new scientific findings and to more rapidly scale up HIV prevention and treatment programs nationally. A recent paper by David Holtgrave, a department chair at the Johns Hopkins Bloomberg School of Public Health, and colleagues found that "[w]ithout expansion of diagnostic services and of prevention services for [people living with HIV], scaling up coverage of HIV care and treatment alone in the U.S. will not achieve the incidence and transmission rate reduction goals of the NHAS. However, timely expansion of testing and prevention services for [people living with HIV] does allow for the goals to still be achieved by 2015, and does so in a highly cost-effective manner." The goals of the NHAS include:

* lowering new HIV infections by 25 percent and HIV incidence by 30 percent

* increasing Americans' knowledge of their own serostatus from 79 percent to 90 percent

* increasing the proportion of newly diagnosed Americans linked to clinical care within three months from 79 percent to 90 percent

* increasing the proportion of Ryan White HIV/AIDS program clients who are in continuous care (at least two visits for routine HIV medical care in 12 months at least 3 months apart) from 73 percent to 80 percent

* increasing the percentage of Ryan White HIV/AIDS program clients with permanent housing from 82 percent to 86 percent, and

* increasing the proportion of HIV-diagnosed gay and bisexual men, Blacks, and Latinos/Latinas with undetectable viral load by 20 percent each all by the end of 2015.

Recent scientific discoveries have shown that earlier initiation of antiretroviral therapy can reduce HIV transmission by a whopping 96 percent among couples with differing HIV status.

This led Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) to write:

The fact that treatment of HIV-infected adults is also prevention gives us the wherewithal, even in the absence of an effective vaccine, to begin to control and ultimately end the AIDS pandemic....For the first time in the history of HIV/AIDS, controlling and ending the pandemic are feasible; however, a truly global essential. Major investments in implementation now will save even greater expenditures in the future; and in the meantime, countless lives can be saved.

Revising the National AIDS Strategy to incorporate these new findings could enable the administration to set more ambitious targets of reducing HIV transmission and incidence by 50 percent or more - as South Africa has committed to doing by 2016 - increasing linkage to care to 95 percent, increasing Ryan White care retention to 95 percent (the program funds care for those who cannot otherwise afford it), increasing Ryan White clients' access to housing to 95 percent, and increasing the proportion of blacks, Latinos and Latinas, and gay men with an undetectable viral load to at least 90 percent.

Of course, this revised National AIDS Strategy would cost more money up front. But as Fauci pointed out above, and as Bernhard Schwartländer of UNAIDS, who first proposed the scale-up efforts that led to PEPFAR and the Global Fund in a pivotal paper in Science magazine in 2001, and colleagues pointed out in their global strategic investment framework for HIV: "[t]he yearly cost of achievement of universal access to HIV prevention, treatment, care, and support by 2015 is estimated at no less than US $22 billion. Implementation of the new investment framework would avert 12.2 million new HIV infections and 7.4 million deaths from AIDS between 2011 and 2020 compared with continuation of present approaches, and result in 29.4 million life-years gained. The framework is cost effective at $1060 per lifeyear gained, and the additional investment proposed would be largely offset from savings in treatment costs alone."

6. Increase funding for the National Institutes of Health (NIH) by 15 percent annually for the next five years. The NIH budget has been flatlined since 2004, with the exception of two years of stimulus funding in 2010-2011. The rate at which new grant applications are funded has fallen to 10 percent, meaning nine out of 10 applications are rejected. In his 2011 State of the Union address, Obama committed to reinvigorating the United States' commitment to and investment in scientific research:

This is our generation's Sputnik moment. Two years ago, I said that we needed to reach a level of research and development we haven't seen since the height of the Space Race. And in a few weeks, I will be sending a budget to Congress that helps us meet that goal. We'll invest in biomedical research, information technology, and especially clean energy technology -- an investment that will strengthen our security, protect our planet, and create countless new jobs for our people.

This year, his proposed 2013 budget flatlines NIH once again. We need increased investment in biomedical research to assure the discovery and development of the innovative tools we need to end the epidemic, cure HIV and find a vaccine to prevent its transmission.

7. Commit the administration to fully funding the research, prevention, care, and treatmentscale-up required to end the pandemic. Some of the steps needed to end AIDS are discussed in a report issued this week by our colleagues at AVAC and amfAR, An Action Agenda to End AIDS.

President Obama has shown himself capable of the vision to create a National HIV/AIDS Strategy and continued to ensure that the United States is the leader in support for global HIV programs. Now is the time for him to embrace the newest scientific results, which give America the power to map out an endgame for the epidemic around the world.

AfricaFocus Bulletin is an independent electronic publication providing reposted commentary and analysis on African issues, with a particular focus on U.S. and international policies. AfricaFocus Bulletin is edited by William Minter.

AfricaFocus Bulletin can be reached at Please write to this address to subscribe or unsubscribe to the bulletin, or to suggest material for inclusion. For more information about reposted material, please contact directly the original source mentioned. For a full archive and other resources, see

Read more on |Africa Health|

URL for this file: